FOLFIRINOX

Last updated

FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:

The regimen emerged in 2010 as a new treatment for patients with metastatic pancreatic cancer. [3] [4] [5] A 2011 study published in the New England Journal of Medicine found that FOLFIRINOX produced the longest improvement in survival ever seen in a phase III clinical trial of patients with advanced pancreatic cancer, with patients on the FOLFIRINOX treatment living approximately four months longer than patients receiving the standard gemcitabine treatment (11.1 months compared with 6.8 months). [6] [7] However, FOLFIRINOX is a potentially highly toxic combination of drugs with serious side effects, and only patients with good performance status are candidates for the regimen. [6] [8] Currently FOLFIRINOX is being used as a neoadjuvant therapy, meaning to downstage patients with "borderline and locally advanced" disease with the hope of rendering their tumors amenable to surgical resection. [9]

In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nab-paclitaxel, sold as Abraxane) used with gemcitabine. This regimen may be less toxic—but perhaps less effective—alternative to FOLFIRINOX for treating late-stage pancreatic cancer. Differences in the trials, and the lack of a direct trial comparing the two regimens, preclude a final conclusion. [8] In the United Kingdom, the National Institute for Health and Care Excellence (NICE), in a draft guidance issued in 2014, rejected the use of Abraxane in treatment due to concerns of side effects, efficacy, and cost relative to Gemzar (gemcitabine). [10] However, on 18 May 2017 NICE issued a reappraisal for the use of Abraxane in the UK. This was in response to Celgene putting forward a Patient Access Scheme (PAS) proposal, which would bring down the cost of the drug. [11]

See also

Related Research Articles

<span class="mw-page-title-main">Bladder cancer</span> Urinary system cancer that begins in the urinary bladder

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.

<span class="mw-page-title-main">Pancreatic cancer</span> Type of endocrine gland cancer

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. A number of types of pancreatic cancer are known.

<span class="mw-page-title-main">Gemcitabine</span> Chemical compound

Gemcitabine, sold under the brand name Gemzar, among others, is a chemotherapy medication used to treat cancers. It is used to treat testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is administered by intravenous infusion. It acts against neoplastic growth, and it inhibits the replication of Orthohepevirus A, the causative agent of Hepatitis E, through upregulation of interferon signaling.

<span class="mw-page-title-main">Oxaliplatin</span> Pharmaceutical drug

Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication used to treat colorectal cancer. It is given by injection into a vein.

FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.

<span class="mw-page-title-main">Irinotecan</span> Cancer medication

Irinotecan, sold under the brand name Camptosar among others, is an anti-cancer medication used to treat colon cancer and small cell lung cancer. For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:

IFL is a chemotherapy regimen for treatment of certain cancers, consisting of concurrent treatment with irinotecan, leucovorin, and fluorouracil.

<span class="mw-page-title-main">Breast cancer chemotherapy</span>

Breast cancer chemotherapy refers to the use of cytotoxic drugs (chemotherapy) in the treatment of breast cancer.

Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division. In this formulation, paclitaxel is bonded to albumin as a delivery vehicle. It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".

<span class="mw-page-title-main">Evofosfamide</span> Chemical compound

Evofosfamide is a compound being evaluated in clinical trials for the treatment of multiple tumor types as a monotherapy and in combination with chemotherapeutic agents and other targeted cancer drugs.

Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer. The role of FOLFOXIRI in colorectal cancer has been reviewed.

<span class="mw-page-title-main">Trastuzumab deruxtecan</span> Medication

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell.

References

  1. ↑ Moran, R. G.; Keyomarsi, K. (1987). "Biochemical rationale for the synergism of 5-fluorouracil and folinic acid". NCI Monographs (5): 159–63. PMID   2963229.
  2. ↑ "Leucovorin".
  3. ↑ Conroy, T; Gavoille, C; Samalin, E; Ychou, M; Ducreux, M (2013). "The role of the FOLFIRINOX regimen for advanced pancreatic cancer". Current Oncology Reports. 15 (2): 182–189. doi:10.1007/s11912-012-0290-4. PMID   23341367. S2CID   36317669.
  4. ↑ Faris, JE; Blaszkowsky, LS; McDermott, S; et al. (2013). "FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience". Oncologist. 18 (5): 543–548. doi:10.1634/theoncologist.2012-0435. PMC   3662845 . PMID   23657686.
  5. ↑ "FOLFIRINOX". Pancreatic Cancer Association. Archived from the original on 17 September 2013. Retrieved 6 September 2013.
  6. 1 2 "Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients". National Cancer Institute. 7 June 2011. Retrieved 6 September 2013.
  7. ↑ Conroy, T; Desseigne, F; Ychou, M; et al, on behalf of Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup (2011). "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer". New England Journal of Medicine . 364 (19): 1817–1825. doi: 10.1056/nejmoa1011923 . PMID   21561347.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. 1 2 Thota, R; Pauff, JM; Berlin, JD (January 2014). "Treatment of metastatic pancreatic adenocarcinoma: a review". Oncology (Williston Park, N.Y.). 28 (1): 70–4. PMID   24683721.
  9. ↑ Michelakos, T; Pergolini, I; Castillo, CF; Honselmann, KC; Cai, L; Deshpande, V; Wo, JY; Ryan, DP; Allen, JN; Blaszkowsky, LS; Clark, JW; Murphy, JE; Nipp, RD; Parikh, A; Qadan, M; Warshaw, AL; Hong, TS; Lillemoe, KD; Ferrone, CR (April 2019). "Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX". Annals of Surgery. 269 (4): 733–740. doi:10.1097/SLA.0000000000002600. PMID   29227344. S2CID   206074649.
  10. ↑ "The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance" (Press release). National Institute for Health and Care Excellence. 30 December 2014. Retrieved 29 March 2022.
  11. ↑ "Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE" (Press release). National Institute for Health and Care Excellence. 4 August 2017. Retrieved 8 March 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.